Mirati Therapeutics Inc. Stock
Mirati Therapeutics Inc. Stock
Pros and Cons of Mirati Therapeutics Inc. in the next few years
Pros
Cons
Performance of Mirati Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Mirati Therapeutics Inc. | - | - | - | - | - | - | - |
| Ironwood Pharmaceuticals | 6.210% | 4.054% | 1.987% | -18.085% | -24.510% | -15.847% | - |
| Sage Therapeutics Inc. | -3.520% | 1.448% | -19.076% | -68.390% | -35.200% | -80.196% | - |
| Novocure Ltd | 2.120% | 16.088% | 3.044% | -77.020% | -3.958% | -91.837% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Mirati Therapeutics Inc. (NASDAQ: MRTX) is a biotechnology firm specializing in the research and development of a wide range of therapeutics. Based on the extensive financial data provided, it becomes clear that the company has positioned itself solidly within its industry. However, the financials also present an image of a company likely in the growth stage, reinvesting heavily into its business, research and development, and facing substantial operational expenditures.
Increased Investment in Research & Development: With year-on-year increases in research and development expenses from 2020 to 2022, the firm reflects a committed approach towards its future growth. Higher R&D expenses often indicate towards promising future prospects and potential products in the pipeline.
Cash Reserves: The company has been maintaining considerable cash reserves over the past years. This is an excellent sign as it provides the firm with the financial capacity to steer through unexpected contingencies and business slowdowns.
Comments